



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁶: A61K 38/00, 38/12, 38/14, C07K 9/00 | A1 | (11) International Publication Number: WO 97/38702 (43) International Publication Date: 23 October 1997 (23.10.97) |
| (21) International Application Number: PCT/US97/05659 (22) International Filing Date: 7 April 1997 (07.04.97) (30) Priority Data: 60/015,330 12 April 1996 (12.04.96) US 60/031,736 25 November 1996 (25.11.96) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): STACK, Douglas, R. [US/US]; 12228 Wesley Place, Fishers, IN 46038 (US). THOMPSON, Richard, C. [US/US]; 763 North County Road, 900 West, Frankfort, IN 46041 (US). (74) Agents: PAGE, Kathleen, R., S. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). | | (81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: COVALENTLY-LINKED GLYCOPEPTIDE DIMERS (57) Abstract The present invention is directed to certain glycopeptide dimers in which two glycopeptide units are covalently linked to one another through a modifiable amine on a saccharide. These dimers are useful as antibacterials, especially for the control of gram positive bacteria; the compounds are particularly useful for the control of resistant bacterial strains, such as vancomycin-resistant-enterococci ("VRE"). | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SR | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

-1-

COVALENTLY-LINKED GLYCOPEPTIDE DIMERS

The present invention is directed to glycopeptide dimers covalently linked to one another through an amine function of
5 an amino sugar. The invention is further directed to antibacterial methods employing, and pharmaceutical formulations comprising, such glycopeptide dimers.

Glycopeptides are a class of antibiotics; see, e.g., "Glycopeptide Antibiotics", edited by Nagarajan (Marcel
10 Dekker, Inc., 1994). Two of them, vancomycin and teicoplanin, are sold as antibacterial products for the control of gram positive bacterial infections. Vancomycin, the earlier-discovered of the two, was used for several decades with no bacterial resistance emerging. However, in
15 the late 1980s, resistance was detected (Lancet I, 1988, 57-88). Such resistance has increased in the years since then; see "Nosocomial Enterococci resistant to Vancomycin -- United States, 1989-1993", MMWR Morbid Mortal Wkly. Rep. (Centers for Disease Control and Prevention). Resistance can be to
20 either or both of these antibiotics, and/or also to methicillin. Resistant organisms have become common in nosocomial settings, presenting special risks for immunocompromised persons. Resistant bacteria present a formidable challenge to society.

25 The present invention provides a new tool in the armamentarium for controlling resistant bacteria.

The present invention is directed to glycopeptide dimers which are covalently linked through an amine function of an

-2-

amino sugar. The identity of the glycopeptide is not critical, except that it comprises a modifiable amine on a sugar. Preferred glycopeptides are those of the vancomycin type, also known as dalbaheptides (J. Antibiotics, Dec., 5 1989, page 1892).


Representative glycopeptides include:

vancomycin,
A82846A,
A82846B,
10 A82846C,
PA-42867-A,
PA-42867-C,
PA-42867-D,
A83850A,
15 A83850B,
actinoidin,
avoparcin,
galacardin,
helevecardin, and
20 M47767.


The linking group which functions to covalently link the two glycopeptide units is similarly not critical. The present dimers are most conveniently prepared by the reaction of the glycopeptide and a bisaldehyde, followed by reduction.
25 Therefore, the linking group is the chemical unit internal to the aldehyde groups of any bisaldehyde.

In one embodiment, the present invention is directed to specific dimer compounds defined by Formula I:

-3-




In the above formulae, each of G and G' is independently
 5 selected from the group consisting of deshydrovancomycin of
 the formula:



and deshydroA82846B of the formula:

-4-



wherein Y^1 is OH or $\begin{smallmatrix} Y^2 \\ -N- \\ Y^2 \end{smallmatrix}$ and Y^2 is defined as follows:

(1) each Y^2 independently represents

5 hydrogen,

alkyl of C_1 - C_{10} ,

cycloalkyl of C_5 - C_6 .

cycloalkenyl of C_5 - C_6 ,

naphthyl,

10 biphenyl,

radical of the formula $-Y^3-(Y^4)_0, 1, \text{ or } 2$, wherein Y^3 is loweralkyl of C_1 - C_6 optionally substituted by from one to three substituents, each of which is independently selected from the group consisting of halo, nitro, cyano, alkoxy,

15 haloalkyl, and haloalkoxy; and Y^4 is $\begin{smallmatrix} Y^5 \\ -N- \\ Y^5 \end{smallmatrix}$ wherein Y^5 is

-5-

independently hydrogen or loweralkyl of C₁-C₄, or Y⁴ is phenyl or phenyl substituted with from one to three substituents, each of which is independently

halo,

5 nitro,

loweralkyl of C₁-C₄,

cycloalkyl of C₅-C₆,

loweralkoxy of C₁-C₄,

haloloweralkyl of C₁-C₄, or

10 haloloweralkoxy of C₁-C₄; or

(2) one Y² is hydrogen and the other Y² is (2-furanon-3-yl);

or

(3) both Y²s are taken together with the nitrogen and

constitute a five- to seven-membered heterocyclic ring

15 optionally containing in addition to the indicated nitrogen

atom one additional hetero ring atom which is nitrogen,


oxygen, or sulfur, and which heterocyclic radical can be

unsubstituted or substituted with from one or two

substituents, each of which is loweralkyl of C₁-C₂,


20 loweralkoxy of C₁-C₂, phenyl, benzyl, or C₁-C₆-alkanoyl;

and L is a divalent linking radical of the formula A:





25 wherein A is:

-6-

alkylene of C₁-C₁₆,(alkylene of C₁-C₄-X')_q-alkylene of C₁-C₄, wherein q is 1-3,

5

10 each R¹ is independentlyCH₂,

O,



S,

15

$$\begin{array}{c} \text{-N-} \\ | \\ \text{R}^2 \end{array},$$

$$\begin{array}{c} \text{O} \\ || \\ \text{-X-C-} \end{array} \text{ or } \begin{array}{c} \text{O} \\ || \\ \text{-C-X-} \end{array},$$

-7-



5 wherein each R independently represents halo, loweralkyl of C₁-C₆, loweralkoxy of C₁-C₆, phenyl, or phenyl substituted by from 1 to 2 substituents, each of which is independently halo, loweralkyl of C₁-C₆, or loweralkoxy of C₁-C₆; each X is independently -O- or -N- wherein R² is H or loweralkyl of

10


C₁-C₄; and each X' is independently -O-, -S-, or -N- wherein

R² is as defined above; or L is a divalent linking radical of the formula B:

15

B. -alkylene of C₁-C₈-R³-X"-R³-alkylene of C₁-C₈-

wherein X" represents alkylene of C₁-C₄ or a phenylene of the formula



20

-8-

wherein R is as defined above; and each R³ is independently CH₂ or O. Salts of the foregoing dimers can be used.

In compounds of Formula I, the glycopeptide units, G and G', may be identical or different. Any "alkylene" of C₂ or
5 higher can be straight chain or branched.

Certain compounds are preferred. Symmetrical compounds (G=G' and/or both R¹ are identical), are preferred for their more efficient synthesis.

Antibacterial activity is enhanced by employing
10 preferred "L" groups. Preferences include the following, individually and in any combination:

L = a linking radical of formula A

L = a linking radical of formula B wherein the carbon attached to -CH₂-G or to -CH₂-G' is branched

15 R¹ = O

A = alkylene of C₁-C₁₆, especially straight-chain and especially C₆-C₁₂;

A = (alkylene of C₁-C₄-X')_q-alkylene of C₁-C₄, especially wherein X'=O; the alkylene is -(CH₂)₂-;

20 and q=2;

R = phenyl and substituted phenyl, especially chlorophenyl; and especially when R has this value on a phenyl ring within "A".










25 Other preferences will be apparent from the further teachings herein.








Representative dimers of Formula I are set forth in following TABLE 1.







TABLE 1

| Ex. # | G | G' | L | Name |
|-------|-------|-------|--|---|
| 1 | Vanco | Vanco | <chem>*c1ccc(cc1)OCCOc2ccc(cc2)*</chem> | 1,2-ethanediyl-bis-(4,1-phenylene)methylene-bis-[vancomycin] |
| 2 | Vanco | Vanco | <chem>*c1ccccc1OCCCOc2ccccc2*</chem> | 1,4-butanediyl-bis-(2,1-phenylene)methylene-bis-[vancomycin] |
| 3 | Vanco | Vanco | <chem>*c1ccc(cc1)OCCCCOc2ccc(cc2)*</chem> | 1,5-pentanediyl-bis-[(oxy-4,1-phenylene)methylene]-bis-[vancomycin] |
| 4 | Vanco | Vanco | <chem>*c1ccccc1OCCCCOc2ccccc2*</chem> | 1,5-pentanediyl-bis-[(oxy-3,1-phenylene)methylene]-bis-[vancomycin] |
| 5 | Vanco | Vanco | <chem>*c1ccc(cc1)OCCCCCOc2ccc(cc2)*</chem> | 1,6-hexanediyl-bis-(oxy-4,1-phenylene)methylene-bis-[vancomycin] |
| 6 | Vanco | Vanco | <chem>*c1ccc(cc1)OCC(C)CCCCOc2ccc(cc2)*</chem> | 3-methyl-1,5-pentanediyl-bis[(oxy-4,1-phenylene)methylene]-bis-[vancomycin] |
| 7 | Vanco | Vanco | <chem>*c1ccc(cc1)OCCCCCCOc2ccc(cc2)*</chem> | 1,7-heptanediyl-bis-(oxy-4,1-phenylene)methylene-bis-[vancomycin] |
| 8 | Vanco | Vanco | <chem>*c1ccc(cc1)OCCCCCOCCOc2ccc(cc2)*</chem> | 1,8-octanediyl-bis-(oxy-4,1-phenylene)methylene-bis-[vancomycin] |







| Ex. # | G | G' | L | Name |
|-------|---------|---------|---|--|
| 9 | Vanco | Vanco | | 1,9-nonanediyl-bis-4,1-phenylene-bis-methylene-bis-vancomycin |
| 10 | Vanco | Vanco | | 1,2-ethanediyl-bis-1,2-ethylenedioxy-4,1-phenylene-bis-methylene-bis-vancomycin |
| 11 | Vanco | Vanco | | 1,4-phenylene-bis-1,4-carbonyloxy-1,2-ethylenedioxy-2,1-phenylene-bis-methylene-bis-vancomycin |
| 12 | Vanco | Vanco | | 1,3-phenylene-bis-1,3-n-propylenedioxy-4,1-phenylene-bis-methylene-bis-vancomycin |
| 13 | A82846B | Vanco | | 1,8-octanediyl-bis-4,1-phenylene-bis-methylene-bis-vancomycin [A82846B] |
| 14 | A82846B | A82846B | | 1,3-propanediyl-bis-1,3-n-propylenedioxy-4,1-phenylene-bis-methylene-bis-A82846B |
| 15 | A82846B | A82846B | | 1,4-butanediyl-bis-2,1-phenylene-bis-methylene-bis-A82846B |
| 16 | A82846B | A82846B | | 1,5-pentanediyl-bis-1,5-pentanedioxy-4,1-phenylene-bis-methylene-bis-A82846B |

| Ex. # | G | G' | L | Name |
|-------|---------|---------|--|---|
| 17 | A82846B | A82846B |  | 1,5-pentanediy1-bis-[(oxy-3,1-phenylene)-methylene]-bis-[A82846B] |
| 18 | A82846B | A82846B |  | 1,6-hexanediy1-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |
| 19 | A82846B | A82846B |  | 1,7-heptanediy1-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |
| 20 | A82846B | A82846B |  | 1,8-octanediy1-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |
| 21 | A82846B | A82846B |  | 1,9-nonanediy1-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |
| 22 | A82846B | A82846B |  | 1,8-octanediy1-bis-[(oxy-3,1-phenylene)-methylene]-bis-[A82846B] |
| 23 | A82846B | A82846B |  | 1,8-octanediy1-bis-[(oxy-3-n-pentyloxy-4,1-phenylene)methylene]-bis-[A82846B] |
| 24 | A82846B | A82846B |  | 1,9-nonanediy1-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |
| 25 | A82846B | A82846B |  | 1,9-nonanediy1-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |



| Ex. # | G | G' | L | Name |
|-------|---------|---------|--|--|
| 26 | A82846B | A82846B |  | 1,10-decanediyl-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |
| 27 | A82846B | A82846B |  | 1,12-dodecanediyl-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |
| 28 | A82846B | A82846B |  | 1,16-hexadecanediyl-bis-[(oxy-4,1-phenylene)-methylene]-bis-[A82846B] |
| 29 | A82846B | A82846B |  | 1,2-ethanediyl-bis-[(oxy-1,2-ethylenedioxy-4,1-phenylene)methylene]-bis-[A82846B] |
| 30 | A82846B | A82846B |  | 1,3-phenylene-bis-[(oxy-1,3-n-propylenedioxy-4,1-phenylene)methylene]-bis-[A82846B] |
| 31 | A82846B | A82846B |  | 1,4-phenylene-bis-[(carbonyloxy-1,2-ethylenedioxy-2,1-phenylene)methylene]-bis-[A82846B] |
| 32 | A82846B | A82846B |  | 1,3-[5-biphenylyl]-bis-[(oxy-1,3-n-propylenedioxy-4,1-phenylene)methylene]-bis-[A82846B] |

| Ex. # | G | G' | L | Name |
|-------|---------|---------|--|--|
| 33 | A82846B | A82846B |  | 1,6-hexanedibis[oxo-4,4'-biphenylene]-methylenabis (A82846B) |
| 34 | A82846B | A82846B |  | 1,3-phenylenebis[oxo-1,5-n-pentyleneoxy]bis[4,1-phenylene]methylenabis (A82846B) |
| 35 | A82846B | A82846B |  | 1,8-octanedibis[oxo-4-phenyl-3,1-biphenylene]-methylenabis (A82846B) |
| 36 | Vanco | Vanco |  | 1,8-octanedibis-[3,1-phenylene]-bis[vancomycin] |
| 37 | Vanco | Vanco |  | 1,6-hexanedibis[oxo-4,4'-biphenylene]-bis[vancomycin] |
| 38 | Vanco | Vanco |  | 1,8-octanedibis-[oxo-4-iodo-3,1-phenylene]methylenabis[vancomycin] |

| Ex. # | G | G' | L | Name |
|-------|-------|-------|---|---|
| 39 | Vanco | Vanco | The structure shows two vancomycin units connected by a methylene group. Each vancomycin unit is linked to a 3,1-phenylene ring, which is further connected to an 1,8-octanediyl chain. | 1,8-octanediylbis-[oxy-4-phenyl-3,1-phenylene]-methylenelbis-[vancomycin] |
| 40 | Vanco | Vanco | The structure shows two vancomycin units connected by a hexamethylene chain. Each vancomycin unit is linked to a 5-methyl-5,1-hexylene ring, which is further connected to a 1,3-phenylene ring. | 1,3-phenylene-bis-[oxy-5-methyl-5,1-hexylene]-bis-[vancomycin] |
| 41 | Vanco | Vanco | The structure shows two vancomycin units connected by a butanediyl chain. Each vancomycin unit is linked to a 5-methyl-5,1-hexylene ring, which is further connected to a 1,4-butanediyl chain. | 1,4-butanediylbis-[oxy-5-methyl-5,1-hexylene]-bis-[vancomycin] |
| 42 | Vanco | Vanco | The structure shows two vancomycin units connected by a methylene group. Each vancomycin unit is linked to a 4,1-phenylene ring, which is further connected to a 1,12-dodecanediyl chain. | 1,12-dodecanediylbis-[oxy-4,1-phenylene]-methylenelbis-[vancomycin] |
| 43 | Vanco | Vanco | The structure shows two vancomycin units connected by a methylene group. Each vancomycin unit is linked to a 4,1-phenylene ring, which is further connected to a 1,3-n-propyleneoxy chain, which is then connected to a 1,3-phenylene ring. | 1,3-phenylene-bis-[oxy-1,3-n-propyleneoxy-4,1-phenylene]methylenelbis-[vancomycin]·3HCl salt |
| 44 | Vanco | Vanco | The structure shows two vancomycin units connected by a methylene group. Each vancomycin unit is linked to a 4,1-phenylene ring, which is further connected to a 1,3-n-propyleneoxy chain, which is then connected to a 1,3-phenylene ring. The 1,3-phenylene ring is also connected to a 5-n-pentyl chain. | 5-n-pentyl-1,3-phenylene-bis[(oxy-1,3-n-propyleneoxy-4,1-phenylene)methylenelbis-[vancomycin] |

| Ex. # | G | G' | L | Name |
|-------|---|---------|--|--|
| 45 | A82846B | A82846B |  | 1,8-octanediylbis-(4-iodo-3,1-phenylene)methylene bis- (A82846B) |
| 46 | A82846B | A82846B |  | 1,3-phenylene-bis-(5-methyl-5,1-hexylene)-bis (A82846B) |
| 47 | A82846B | A82846B |  | 1,3-phenylene-bis-(1,7-n-heptyleneoxy-4,1-phenylene)methylene bis- (A82846B) |
| 48 | A82846B | A82846B |  | 1,4-butanediylbis-(oxy-5-methyl-5,1-hexylene)-bis- (A82846B) |
| 49 | A82846B | A82846B |  | 1,3-phenylene-bis-(oxy-1,3-n-propyleneoxy-4,1-phenylene)methylene bis (A82846B) |
| 50 | A82846B, (3-dimethylamino propyl)-amide | A82846B |  | 1,3-phenylenebis(oxy-1,3-n-propyleneoxy-4,1-phenylene)methylene bis- A82846B/A82846B, (3-dimethylaminopropyl)amide |

-16-

| Ex. # | G | G' | L | Name |
|-------|---|---|--|--|
| 51 | A82846B, (3- dimethyla mino propyl)- amide | A82846B, (3- dimethyl amino propyl)- amide |  | 1,3-phenylenebis[oxy-1,3-n-propylene-oxy-4,1-phenylene)methylene]bis[A82846B, (3-dimethylaminopropyl)-amide] |
| 52 | A82846B, desleucyl | A82846B, desleucyl |  | 1,3-phenylene-bis-[(oxy-1,3-n-propyleneoxy-4,1-phenylene)methylene]--bis[desleucylA82846B] |

-17-

The dimers of the present invention are prepared by reacting a glycopeptide with a bisaldehyde to form an intermediate Schiff base, which is subsequently reduced to obtain the dimers.

- 5 Many bisaldehydes are known compounds. They can be prepared by techniques known to those skilled in the art, per various references;


- J. Org. Chem., 26, 474, (1961)
J. Het. Chem., 27, 1007 (1990)
10 J.A.C.S., 73, 1872 (1951)
J.A.C.S., 109, 2260 (1987)
J. Chem. Soc. Perkin I, 189 (1983)
Syn. Comm., 18(12), 1379 (1988)
Chem. Letters, 587 (1995)
15 Macromolecules, 6045 (1992);
J. Chem. Soc. Chem. Comm. 1463 (1991)
J. Polym. Sci. Part A. Polymer Chem. 31(12) 2899 (1993)
J. Chem. Res. Synop. (8), 296 (1994)
Farmco Ed. Sci. 15, 468 (1960)
20 Makromol. Chem. 191 (4) 815 (1990)
J. Polym. Sci. Part A. Polymer Chem. 29(3) 361 (1991)
Makromol. Chem. 65, 54 (1963)

- The reaction of bisaldehyde with glycopeptide is carried
25 out in accordance with prior art condensations of amine and aldehyde to form Schiff bases, and their subsequent reduction.

-18-

Thus, the present condensation is typically conducted in a polar solvent, such as dimethylformamide or methanol, or a mixture of polar solvents. The reaction goes forward over a range of temperatures, such as from 25°C to 100°C, but is preferably conducted at temperatures of about 60°C to 70°C. The reaction is preferably conducted under an inert atmosphere, such as nitrogen or argon. The reaction requires two molecular proportions of glycopeptide and one molecular proportion of bisaldehyde.

10 The reaction yields a Schiff base of the formula



The Schiff base is subsequently reduced. Preferably, the reduction is conducted in the same reaction mixture in a polar solvent, and employing a chemical reducing agent.

15 Metal borohydrides, such as sodium borohydride and sodium cyanoborohydride are preferred. The reaction goes forward over a range of temperatures, such as from about 25°C to about 100°C; preferably, the reaction is conducted at about 60°C to 70°C.

20 The product, or mixture of products, can be isolated and purified if desired in a conventional manner, such as by HPLC. Characterization of products is best accomplished by Fast Atom Bombardment Mass Spectroscopy (FAB•MS).

25 In addition to the foregoing synthetic route, compounds of the present invention can be prepared in an alternate route. In this alternate route, a dimer is prepared by the foregoing synthetic route, and further changes to the structure of the glycopeptide are made subsequently. This

-19-

approach to synthesizing the present dimers is illustrated by Preparations 6-8 below. In Preparations 6-7, a dimer of the present invention is reacted with an amine to convert the acid of the glycopeptide to an amide ($Y^1 = -N \begin{smallmatrix} Y^2 \\ \diagup \end{smallmatrix}$). In

5 Preparation 8, a dimer of the present invention is subjected to Edman degradation to obtain the corresponding desleucyl dimer. Other modifications of the glycopeptide portion of a dimer can likewise be made. Techniques for such modifications are known to those skilled in the art; see
10 Glycopeptide Antibiotics, *supra*, and references cited therein. This volume is incorporated herein by reference.

When it is desired to employ a salt, a compound of Formula I can be reacted with a mineral or organic acid or an inorganic base, in techniques well known to those skilled in
15 the art. Pharmaceutically-acceptable salts are preferred.

The following examples report preparations of illustrative dimers.

The HPLC procedures reported in these examples were as follows:

20 Analytical ("Conditions A"): Reactions were monitored by analytical HPLC using a Waters μ Bondapak C₁₈ column (3.9x300 mm) and UV detection at 280 nm. Elution was accomplished with a linear gradient of 5% CH₃CN - 95% buffer to 80% CH₃CN - 20% buffer over 30 minutes. The buffer used
25 was 0.5% triethylamine in water, adjusted to pH 3 with H₃PO₄.

Preparative ("Conditions B"): Crude reaction mixtures were purified by preparative HPLC using a Waters C₁₈ Nova-Pak

-20-

column (40x300 mm) and UV detection at 280 nm. Elution was accomplished with a linear gradient of 5% CH₃CN - 95% buffer to 80% CH₃CN - 20% buffer over 30 minutes. The buffer used was 0.5% triethylamine in water, adjusted to pH 3 with H₃PO₄.


- 5 The desired fractions were subsequently desalted with a Waters C₁₈ Sep-Pak (35 cc) followed by lyophilization. Alternatively, a buffer containing 0.1% TFA in H₂O can be used, in which case the TFA salt is obtained directly after lyophilization.
- 10 Compounds were desalted as follows. A Waters Sep-Pak cartridge was pre-wet with methanol (2-3 column volumes) then conditioned with water (2-3 column volumes). The sample, dissolved in a minimum volume of water, was loaded onto the Sep-Pak column which was then washed with water (2-3 column
- 15 volumes) to remove the unwanted salts. The product was then eluted with an appropriate solvent system, typically 1:1 CH₃CN/H₂O, CH₃CN, and/or methanol. The organic solvent component was removed *in vacuo* and the resulting aqueous solution lyophilized to give the final product.

-21-

Preparation 1:

Synthesis of Example 5, 1,6-hexanediylbis[(oxy-4,1-phenylene)methylene]bis[vancomycin]
(one-pot synthesis of vancomycin dimer)

5



A dry 100 mL round bottom flask was charged with vancomycin•HCl (250 mg, 0.168 mmol.), and 1,6-bis(4'-formylphenoxy)-n-hexane (101 mg, 0.310 mmol.). Anhydrous DMF (6 mL) was added to the flask and the resulting mixture was stirred under N₂ and heated to 70°C. After 3.5 hours, sodium cyanoborohydride (80 mg, 1.3 mmol.) was added in one portion, and the reaction mixture was maintained at 70°C for one additional hour. The reaction mixture was cooled, and stored at 0°C overnight.

The reaction mixture was then concentrated in vacuo to give a residue which was re-dissolved in 1:1 H₂O:CH₃CN (5 mL) and HOAc (0.5 mL). The resulting solution was purified by preparatory HPLC (conditions B). The desired fractions, as determined by analytical HPLC (conditions A), were concentrated in vacuo to ~ 1.5 mL, and desalted. After lyophilization, 1,6-hexanediylbis[(oxy-4,1-phenylene)methylene]bis[vancomycin] was obtained (24.3 mg, 0.008 mmol., 10.0 % yield) as a white powder.


-22-

HPLC (conditions A) retention time: 13.6 min.

FABMS shows peak of (M+6H) at 3195.

Preparation 2:

5 Synthesis of Example 25, 1,9-nonanedivlbis[(oxy-4,1-
 phenylene)methylenelbis[A82846B]
 (one-pot synthesis of A82846 dimer)



10

A dry 100 mL round bottom flask was charged with A82846B·tri-acetate salt (278 mg, 0.157 mmol.), and 1,9-bis-(4'-formylphenoxy)-n-nonane (103.7 mg, 0.282 mmol.). Anhydrous DMF (15 mL) and anhydrous MeOH (15 mL) were added to the flask and the resulting mixture was stirred under N₂ and heated to 70°C. After 3.5 hours, sodium cyanoborohydride (68 mg, 1.08 mmol.) was added in one portion, and the reaction mixture was maintained at 70°C for one additional hour.

20 The reaction mixture was then concentrated in vacuo to give a residue which was re-dissolved in 1:1 H₂O:CH₃CN (5 mL) and HOAc (0.5 mL). The resulting solution was purified by preparatory HPLC (conditions B). The desired fractions, as determined by analytical HPLC (conditions A), were
25 concentrated in vacuo to ~ 1.5 mL, and desalted. After

-23-

lyophilization, 1,9-nonanediylbis[(oxy-4,1-phenylene)methylene]bis[epivancomycin] was obtained (25.7 mg, 0.007 mmol., 9.3 % yield) as a white powder.


HPLC (conditions A) retention time: 14.9 min.

5 FABMS shows peak of (M+5H) at 3522.

Preparation 3:

Synthesis of Example 13, 1,8-octanediylbis[(oxy-4,1-phenylene)methylene][vancomycin][A82846B]

10 (synthesis of hybrid dimer)



A dry round bottom flask was charged with vancomycin•HCl (75 mg, 0.052 mmol.), and N⁴-(4-(8-(p-formylphenoxy)-n-octyloxy)benzyl)A82846B (50 mg, 0.026 mmol.) (see Preparation 4). Anhydrous DMF (6 mL) was added to the flask and the resulting mixture was stirred under N₂ and heated to 70°C. After 5 hours, sodium cyanoborohydride (59 mg, 0.93 mmol.) was added in one portion, and the reaction mixture was maintained at 70°C for one additional hour. The reaction mixture was cooled, and stored at 0°C overnight.

The reaction mixture was then concentrated in vacuo to give a residue which was re-dissolved in 1:1 H₂O:CH₃CN (5 mL) and HOAc (0.5 mL). The resulting solution was purified by

-24-

preparatory HPLC (conditions B). The desired fractions, as determined by analytical HPLC (conditions A), were concentrated in vacuo to ~ 1.5 mL, and desalted. After lyophilization, 1,8-octanediylbis[(oxy-4,1-phenylene)methylene][vancomycin][A82846B] was obtained (5.2 mg, 0.002 mmol., 7.6 % yield) as a white powder.

HPLC (conditions A) retention time: 14.5 min.


FABMS shows peak of (M+6H) at 3364.

10

Preparations 4 & 5:

Synthesis of Example 47, N⁴-(4-(8-(p-formylphenoxy)-n-octyloxy)benzyl)A82846B, and Example 21, 1,8-octanediylbis[(oxy-4,1-phenylene)methylene]bis[A82846B] (two-step synthesis of A82846 dimer)

15



A dry flask was charged with A82846B·tri-acetate salt (5.0 g, 0.003 mol.), and 1,8-bis(4'-formylphenoxy)-n-octane (1.93 g, 0.006 mol.). Anhydrous DMF (300 mL) and anhydrous MeOH (300 mL) were added to the flask and the resulting mixture was stirred under N₂ and heated to 70°C. After 3.75 hours, sodium cyanoborohydride (0.76 g, 0.012 mol.) was added in one portion, and the reaction mixture was maintained at

-25-

70°C for one additional hour. The reaction was cooled and stored at 0°C overnight.

The reaction mixture was then concentrated in vacuo to give a residue which was re-dissolved in 1:1 H₂O:CH₃CN (200
5 mL) and HOAc (5 mL). The resulting solution was purified by preparatory HPLC (conditions B). The desired fractions, as determined by analytical HPLC (conditions A), were concentrated in vacuo to ~ 1.5 mL, and desalted. After lyophilization, N⁴-(4-(8-(p-formylphenoxy)-n-
10 octyloxy)benzyl)A82846B was obtained (387.4 mg, 0.2 mmol., 6.6 % yield) as a white powder.

HPLC (conditions A) retention time: 19.9 min.

FABMS shows peak of (M+3H) at 1932.

15 A dry flask was charged with N⁴-(4-(8-(p-formylphenoxy)-n-octyloxy)benzyl)A82846B (20.0 mg, 0.01 mmol), and A82846B (32.9 mg, 0.021 mmol). Anhydrous DMF (3 mL) and anhydrous MeOH (3 mL) were added to the flask and the resulting mixture was stirred under N₂ and heated to 70°C. After 2 hours,
20 sodium cyanoborohydride (5.0 mg, 0.079 mmol) was added in one portion, and the reaction mixture stirred an additional 0.25 hours.

The reaction mixture was then concentrated in vacuo to give a residue which was redissolved in 1:1 H₂O:CH₃CN (5 mL).
25 The resulting solution was purified by preparatory HPLC (conditions D). The desired fraction, as determined by analytical HPLC (conditions A), were concentrated in vacuo to ~1.5 mL, and desalted. After lyophilization, 1,8-

-26-

octanediylbis[(oxy-4,1-phenylene)methylene]bis[A82846B] was obtained (3.0 mg, 0.001 mmol, 8.6 % yield) as a white powder.

HPLC (conditions A) retention time: 13.6 min.

FABMS shows peak of (M+5H) at 3508.

5

Preparations 6 & 7:

Synthesis of Example 50. 1,3-phenylenebis[oxy-1,3-n-propylene-oxy-4,1-phenylene)methylene]A82846B/A82846B. (3-dimethylaminopropyl)amide.

10 and Example 51. 1,3-phenylenebis[oxy-1,3-n-propylene-oxy-4,1-phenylene)methylene]bis[A82846B. (3-dimethylaminopropyl)amide]

A dry round bottom flask was charged with 1,3-phenylene-bis-[(oxy-1,3-n-propyleneoxy-4,1-phenylene)methylene]--
15 bis[A82846B] (50.0 mg, 0.014 mmol) and 1 mL DMSO. PyBOP (14.5 mg, 0.028 mmol) and 3-dimethylaminopropylamine (2.8 mg, 0.028 mmol) were added and the reaction was stirred at room temperature under nitrogen for one hour. The reaction mixture was then concentrated in vacuo to give a residue
20 which was re-dissolved in 1:1 H₂O:CH₃CN (5 mL). The resulting solution was purified by preparatory HPLC (conditions B). The desired fractions, as determined by analytical HPLC (conditions A) were concentrated in vacuo to ~ 1.5 mL, and desalted as in previous examples. After lyophilization 1,3-
25 phenylenebis[oxy-1,3-n-propylene-oxy-4,1-phenylene)methylene]bis[A82846B, (3-dimethylaminopropyl)amide] (6.9 mg, 13.1% yield) and 1,3-phenylenebis[oxy-1,3-n-propylene-oxy-4,1-phenylene)-

-27-

methylene]A82846B/A82846B, (3-dimethylaminopropyl)amide (6.6 mg, 12.8% yield) were obtained as white powders.

1,3-phenylenebis[oxy-1,3-n-propylene-oxy-4,1-phenylene)methylene]bis[A82846B, (3-dimethylaminopropyl)-amide]

HPLC (conditions A) retention time: 13.2 min.

FABMS shows peak of (M+9H) at 3761.

1,3-phenylenebis[oxy-1,3-n-propylene-oxy-4,1-phenylene)-methylene]A82846B/A82846B, (3-dimethylaminopropyl)amide

HPLC (conditions A) retention time: 13.7 min.

FABMS shows peak of (M+6H) at 3674.

Preparation 8:

Synthesis of Example 52. 1,3-phenylene-bis-[(oxy-1,3-n-propyleneoxy-4,1-phenylene)methylene]-bis[desleucylA82846B]

1,3-phenylene-bis-[(oxy-1,3-n-propyleneoxy-4,1-phenylene)methylene]-bis[A82846B] (165.8 mg, 0.0462 mmol) was dissolved in 15 mL H₂O - pyridine (1:1 v/v) and treated with phenyl isothiocyanate (30 µl, 0.25 mmol). The resulting mixture was stirred at room temperature for 1.5 hours at which time HPLC analysis (conditions A) indicated complete consumption of the starting material. The reaction mixture was concentrated in vacuo to give the crude bistiourea derivative as a white powder.

-28-

The crude thiourea intermediate was suspended in 15 mL CH₂Cl₂, cooled to 0°C, then treated with trifluoroacetic acid (0.20 mL). After 1 hour the reaction mixture was warmed to room temperature and stirred an additional 1 hour. An
5 additional 0.20 mL trifluoroacetic acid was added and the mixture was stirred at room temperature for 3 hours. The solvent was removed *in vacuo* and the crude product was purified by preparative HPLC (conditions B). The desired fractions, as determined by analytical HPLC (conditions A)
10 were concentrated *in vacuo* to ~ 1.5 mL, and desalted as in previous examples to give 10.2 mg (7% yield) of 1,3-phenylene-bis-[(oxy-1,3-n-propyleneoxy-4,1-phenylene)methylene]-bis[desleucylA82846B] as a white powder.

FAB-MS: obtained 3333 (M+4)

15 HPLC retention time (conditions A): 15.1 min.

Details concerning the synthesis of all of the compounds of TABLE 1, as well as identifying characteristics, are presented in TABLE 2.

-29-

TABLE 2

| Ex. # | Aldehyde | HPLC * Retention Minutes | % yield | FAB•MS M/Z | M+x H |
|-------|---|--------------------------------|------------|---------------|----------|
| 1 | 1,2-bis(4-formylphenoxy)-n-ethane | 11.5 | 1.86 | 3136 | 3 |
| 2 | 1,4-bis(2-formylphenoxy)-n-butane | 11.8 | 0.79 | 3165 | 4 |
| 3 | 1,5-bis(4-formylphenoxy)-n-pentane | 12.9 | 5.42 | 3178 | 4 |
| 4 | 1,5-bis(3-formylphenoxy)-n-pentane | 13.0 | 4.08 | 3179 | 4 |
| 5 | 1,6-bis(4-formylphenoxy)-n-hexane | 13.6 | 9.05 | 3195 | 6 |
| 6 | 3-methyl-1,5-bis(4-formylphenoxy)-n-pentane | 13.5 | 4.54 | 3193 | 4 |
| 7 | 1,7-bis(4-formylphenoxy)-n-heptane | 14.7 | 5.00 | 3207 | 5 |
| 8 | 1,8-bis(4-formylphenoxy)-n-octane | 15.5 | 3.91 | 3219 | 2 |
| 9 | 1,9-bis(4-formylphenoxy)-n-nonane | 16.4 | 4.41 | 3235 | 4 |
| 10 | 1,2-bis(2-(4-formylphenoxy)-ethoxy)ethane | 12.3 | 1.89 | 3226 | 4 |
| 11 | 1,4-bis(2-(p-formylphenoxy)-ethoxy)carbonyl-benzene | 13.0 | 10.50 | 3331 | 6 |
| 12 | 1,3-bis(3-(p-formylphenoxy)-n-propyloxy)-benzene | 15.5 | 3.10 | 3300 | 4 |
| 13 | 1,8-bis(4-formylphenoxy)-n-octane | 14.5 | 5.95 | 3364 | 4 |
| 14 | 1,3-bis(4-formylphenoxy)-propane | 9.4 | 14.29 | 3436 | 4 |
| 15 | 1,4-bis(2-formylphenoxy)-n-butane | 10.2 | 5.91 | 3452 | 5 |

-30-

| Ex. # | Aldehyde | HPLC * Retention Minutes | % yield | FAB-MS M/Z | M+x H |
|-------|---|--------------------------------|------------|---------------|----------|
| 16 | 1,5-bis(4-formylphenoxy)- n-pentane | 10.4 | 3.86 | 3466 | 5 |
| 17 | 1,5-bis(3-formylphenoxy)- n-pentane | 11.3 | 22.41 | 3465 | 4 |
| 18 | 1,6-bis(4-formylphenoxy)- n-hexane | 11.3 | 5.46 | 3478 | 4 |
| 19 | 3-methyl-1,5-bis(4-formylphenoxy)- n-pentane | 11.3 | 8.14 | 3479 | 4 |
| 20 | 1,7-bis(4-formylphenoxy)- n-heptane | 12.5 | 5.73 | 3494 | 5 |
| 21 | 1,8-bis(4-formylphenoxy)- n-octane | 14.0 | 13.31 | 3508 | 5 |
| 23 | 1,8-bis(3-formylphenoxy)- n-octane | 14.4 | 21.23 | 3508 | 5 |
| 24 | 1,8-bis(4-formyl-2-n-pentyloxyphenoxy)- n-octane | 20.8 | 16.91 | 3680 | 5 |
| 25 | 1,9-bis(4-formylphenoxy)- n-nonane | 14.9 | 9.31 | 3522 | 5 |
| 26 | 1,10-bis(4-formylphenoxy)- n-decane | 15.9 | 8.87 | 3535 | 5 |
| 27 | 1,12-bis(4-formylphenoxy)- n-dodecane | 17.7 | 1.32 | 3565 | 6 |
| 28 | 1,16-bis(4-formylphenoxy)- n-hexadecane | 20.4 | 4.05 | 3625 | 9 |
| 29 | 1,2-bis(2-(4-formylphenoxy)- ethoxy)ethane | 10.2 | 6.28 | 3511 | 4 |
| 30 | 1,3-bis(3-(p-formylphenoxy)- n-propyloxy)- benzene | 15.2 | 22.96 | 3589 | 5 |
| 31 | 1,4-bis(2-(p-formylphenoxy)- ethoxy)carbonyl- benzene | 11.7 | 24.94 | 3615 | 5 |

-31-

| Ex. # | Aldehyde | HPLC * Retention Minutes | % yield | FAB•MS M/Z | M+x H |
|-------|--|--------------------------------|------------|---------------|----------|
| 32 | 5-phenyl-1,3-bis(3-(p-formylphenoxy)-n-propyloxy)-benzene | 16.8 | 12.88 | 3664 | 5 |
| 33 | 1,6-bis(4-(4-formylphenyl)-phenoxy)hexane | 16.2 | 11.58 | 3633 | 5 |
| 34 | 1,3-bis(5-(4-formylphenoxy)-n-pentyloxy)-benzene | 17.04 | 9.31 | 3645 | 6 |
| 35 | 1,8-bis(2-phenyl-5-formylphenoxy)-octane | 18.3 | 10.83 | 3662 | 6 |
| 36 | 1,8-bis(3-formylphenoxy)-n-hexane | 15.3 | 2.1 | 3221 | 4 |
| 37 | 1,6-bis(4-(4'-formylphenoxy)-phenoxy)-n-hexane | 18.2 | 6.1 | 3347 | 6 |
| 38 | 1,8-bis(3-formyl-2-iodophenoxy)-n-hexane | 22.9 | 2.2 | 3471 | 3 |
| 39 | 1,8-bis(2-phenyl-5-formylphenoxy)-n-octane | 19.3 | 2.8 | 3374 | 4 |
| 40 | 1,3-bis(6-(2-dimethyl)-1-hexanaloxo)-benzene | 15.5 | 8.2 | 3229 | 4 |
| 41 | 1,4-bis(6-(2-dimethyl)-1-hexanaloxo)-butane | 13.5 | 6.1 | 3209 | 4 |
| 42 | 1,12-bis(4-formylphenoxy)-n-dodecane | 21.6 | 6.8 | 3278 | 5 |
| 43 | 1,3-bis(3-(p-formylphenoxy)-n-propyloxy)-benzene | HCL SALT | | | |
| 44 | 1,3-bis(3-(p-formylphenoxy)-n-propyloxy)-5-n-pentylbenzene | 36.6 | 12.7 | 3660 | 8 |
| 45 | 1,8-bis(3-formyl-2-iodophenoxy)-n-octane | 17.1 | 5.4 | 3762 | 6 |

-32-

| Ex. # | Aldehyde | HPLC * Retention Minutes | % yield | FAB-MS M/Z | M+x H |
|-------|--|--------------------------------|------------|---------------|----------|
| 46 | 1,3-bis(6-(2-dimethyl)-1-hexanaloxyl)-benzene | 13.3 | 15.5 | 3516 | 5 |
| 47 | 1,3-bis(3-(p-formylphenoxy-n-heptyloxy)-benzene | 19.3 | 1.4 | 3701 | 6 |
| 48 | 1,4-bis(6-(2-dimethyl)-1-hexanaloxyl)-butane | 13.5 | 24.8 | 3495 | 4 |
| 49 | 1,3-bis(3-(p-formylphenoxy-n-propyloxy)-benzene | HCL SALT | | | |
| 50 | 1,3-bis(3-(p-formylphenoxy)-n-propyloxy)-benzene | 13.7 | 12.8 | 3674 | 6 |
| 51 | 1,3-bis(3-(p-formylphenoxy)-n-propyloxy)-benzene | 13.2 | 13.1 | 3761 | 9 |
| 52 | 1,3-bis(3-(p-formylphenoxy)-n-propyloxy)-benzene | 15.1 | 7.0 | 3333 | 4 |

* Conditions A

5 The present glycopeptide dimers are useful for the treatment of bacterial infections. Therefore, in another embodiment, the present invention is directed to a method for controlling a bacterial infection in a host animal, typically a warm-blooded animal, which comprises administering to the

10 host animal an effective, antibacterial amount of a glycopeptide dimer in which two glycopeptide units are covalently linked to one another through an amine function of an amino sugar. In this embodiment, the dimers can be used to control and treat infections due to various bacteria, but

15 especially gram-positive bacteria. In a preferred

-33-

embodiment, the dimers are used to control and treat infections due to bacteria resistant to existing antibacterials. For example, certain bacteria are resistant to methicillin, and yet others are resistant to vancomycin and/or teicoplanin. The present dimers provide a technique for controlling and treating infections due to such resistant bacterial species.

In carrying out this embodiment of the invention, the dimers can be administered by any of the conventional techniques, including the oral route and parenteral routes such as intravenous and intramuscular. The amount of compound to be employed is not critical and will vary depending on the particular compound employed, the route of administration, the severity of the infection, the interval between dosings, and other factors known to those skilled in the art. In general, a dose of from about 0.5 to about 100 mg/kg will be effective; and in many situations, lesser doses of from about 0.5 to about 50 mg/kg will be effective. A compound of the present invention can be administered in a single dose, but in the known manner of antibacterial therapy, a compound of the present invention is typically administered repeatedly over a period of time, such as a matter of days or weeks, to ensure control of the bacterial infection.

Also in accordance with known antibacterial therapy, a dimer of the present invention is typically formulated for convenient delivery of the requisite dose. Therefore, in another embodiment, the present invention is directed to a

-34-

pharmaceutical formulation comprising a dimer of Formula I, in combination with a pharmaceutically-acceptable carrier. Such carriers are well known for both oral and parenteral routes of delivery. In general, a formulation will comprise
5 a dimer in a concentration of from about 0.1 to about 90% by weight, and often from about 1.0 to about 3%.

The antibacterial efficacy of the present dimers is illustrated by following TABLES 3 and 4. The minimal inhibitory concentrations (MICs) were determined using a
10 standard broth micro-dilution assay. TABLE 4 presents a comparison of the activity of illustrative compounds against representative vancomycin-resistant and vancomycin-sensitive enterococci (Enterococcus faecium and Enterococcus faecalis, mean geometric MIC (mcg/mL), as determined by the standard
15 broth micro-dilution assay.

TABLE 3

[illegible]

TABLE 3
In Vitro Antimicrobial Activity
MIC (mcg/ml)/Compound

[illegible]

[illegible]

TABLE 3
In Vitro Antimicrobial Activity
MIC (mcg/ml)/Compound

| Organism | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 |
|--|-----|-----|-----|-------|-------|-------|-------|-----|-------|
| <i>Staphylococcus aureus</i> 446 | 4 | 16 | >64 | 16 | 1 | 1 | 16 | 16 | 2 |
| <i>Staphylococcus aureus</i> 489 | 2 | 8 | 64 | 1 | 1 | 1 | 4 | 4 | 2 |
| <i>Staphylococcus aureus</i> 447 | >64 | >64 | >64 | 64 | 4 | 8 | >64 | >64 | 2 |
| <i>Staphylococcus aureus</i> X400 | 1 | 16 | 32 | 1 | 1 | 0.5 | 4 | 8 | 1 |
| <i>Staphylococcus aureus</i> X778 | 2 | 8 | 32 | 2 | 0.5 | 0.25 | 2 | 4 | 1 |
| <i>Staphylococcus aureus</i> 491 | 2 | 8 | 16 | ≤0.06 | 0.25 | ≤0.06 | 2 | 4 | 0.5 |
| <i>Staphylococcus aureus</i> S13E | 2 | 8 | 64 | 4 | 0.5 | 0.25 | 8 | 8 | 1 |
| <i>Staphylococcus aureus</i> S41199 | 2 | 8 | 64 | 2 | 1 | 0.5 | 8 | 8 | 2 |
| <i>Staphylococcus aureus</i> S41199A | 1 | 4 | 16 | 0.5 | ≤0.06 | ≤0.06 | 2 | 4 | 0.5 |
| <i>Staphylococcus aureus</i> S41199B | 2 | 8 | 64 | 4 | 1 | 0.5 | 8 | 16 | 2 |
| <i>Staphylococcus haemolyticus</i> 109 | 4 | 32 | 32 | 0.25 | 0.25 | 0.25 | 4 | 2 | 0.5 |
| <i>Staphylococcus haemolyticus</i> 419 | 16 | 64 | 64 | >64 | 4 | 16 | 8 | 8 | 2 |
| <i>Staphylococcus epidermidis</i> 270 | 8 | 32 | 64 | 32 | 1 | 2 | 16 | 8 | 1 |
| <i>Enterococcus faecium</i> 180 | 0.5 | 1 | 8 | 0.25 | 0.125 | 1 | 1 | 1 | 0.5 |
| <i>Enterococcus faecium</i> 180-1 | 1 | 1 | 8 | 0.5 | 0.125 | ≤0.06 | 2 | 2 | 0.25 |
| <i>Enterococcus faecalis</i> 2041 | 1 | 4 | 8 | 0.125 | 0.25 | ≤0.06 | 2 | 2 | 0.125 |
| <i>Enterococcus faecalis</i> 276 | 2 | 4 | 8 | 0.25 | 0.5 | 0.125 | 2 | 2 | 0.5 |
| <i>Enterococcus gallinarum</i> 245 | 1 | 2 | 4 | 0.06 | 0.125 | 0.06 | 1 | 0.5 | 0.25 |
| <i>Haemophilus influenzae</i> RD | >64 | >64 | >64 | | | >64 | >64 | | >64 |
| <i>Escherichia coli</i> EC14 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| <i>Streptococcus pyogenes</i> C203 | 4 | 0.5 | 64 | 0.06 | 0.06 | 0.06 | 0.5 | 2 | ≤0.06 |
| <i>Streptococcus pneumoniae</i> P1 | 2 | 1 | 64 | 0.06 | 0.06 | 0.06 | 0.125 | 2 | 0.125 |

TABLE 3
In Vitro Antimicrobial Activity
MIC (mcg/ml)/Compound

| Organism | 35 | 36 | 37 | 38 | 39 | 40 |
|--|-----|------|-----|-----|-----|------|
| <i>Staphylococcus aureus</i> 446 | 16 | 8 | 8 | 8 | >64 | 8 |
| <i>Staphylococcus aureus</i> 489 | 8 | 2 | 2 | 2 | >64 | 2 |
| <i>Staphylococcus aureus</i> 447 | >64 | 16 | 16 | 32 | >64 | 32 |
| <i>Staphylococcus aureus</i> X400 | 4 | 4 | 2 | 4 | >64 | 4 |
| <i>Staphylococcus aureus</i> X778 | 4 | 4 | 2 | 4 | >64 | 4 |
| <i>Staphylococcus aureus</i> 491 | 2 | 1 | 1 | 2 | >64 | 1 |
| <i>Staphylococcus aureus</i> S13E | 8 | 4 | 4 | 4 | >64 | 8 |
| <i>Staphylococcus aureus</i> SAl199 | 32 | 8 | 4 | 4 | >64 | 4 |
| <i>Staphylococcus aureus</i> SAl199A | 8 | 1 | 2 | 2 | >64 | 1 |
| <i>Staphylococcus aureus</i> SAl199B | 8 | 16 | 2 | 4 | >64 | 4 |
| <i>Staphylococcus haemolyticus</i> 109 | 2 | 2 | 8 | 2 | >64 | 2 |
| <i>Staphylococcus haemolyticus</i> 419 | 16 | 8 | 16 | 16 | >64 | 32 |
| <i>Staphylococcus epidermidis</i> 270 | 8 | 4 | 8 | 8 | >64 | 8 |
| <i>Enterococcus faecium</i> 180 | 2 | <.06 | 1 | 2 | 8 | 0.25 |
| <i>Enterococcus faecium</i> 180-1 | 1 | 0.25 | 1 | 1 | 8 | 0.5 |
| <i>Enterococcus faecalis</i> 2041 | 2 | 0.5 | 2 | 2 | 16 | <.06 |
| <i>Enterococcus faecalis</i> 276 | 4 | 0.25 | 1 | 4 | 32 | 0.5 |
| <i>Enterococcus gallinarum</i> 245 | 1 | 0.06 | 1 | 4 | 8 | 0.06 |
| <i>Haemophilus influenzae</i> RD | | >64 | >64 | 4 | >64 | |
| <i>Escherichia coli</i> EC14 | >64 | >64 | >64 | >64 | >64 | >64 |
| <i>Streptococcus pyogenes</i> C203 | 1 | 0.06 | 1 | 16 | 8 | 0.06 |
| <i>Streptococcus pneumoniae</i> PI | 1 | 0.06 | 1 | 8 | 16 | 0.06 |

TABLE 3
In Vitro Antimicrobial Activity
MIC (mcg/ml)/Compound

| Organism | 41 | 42 | 43 | 44 | 45 | 46 |
|---------------------------------|------|-----|-------|-----|-----|-------|
| Staphylococcus aureus 446 | 32 | 64 | 8 | 8 | 8 | 4 |
| Staphylococcus aureus 489 | 1 | 32 | 1 | 4 | 2 | 1 |
| Staphylococcus aureus 447 | >64 | >64 | 8 | 16 | 32 | 64 |
| Staphylococcus aureus X400 | 4 | 32 | 2 | 8 | 2 | 1 |
| Staphylococcus aureus X778 | 8 | 16 | 2 | 4 | 2 | 1 |
| Staphylococcus aureus 491 | 1 | 8 | 1 | 2 | 2 | 0.5 |
| Staphylococcus aureus S13E | 8 | >64 | 2 | 16 | 4 | 1 |
| Staphylococcus aureus S1199 | 16 | 32 | 2 | 8 | 2 | 1 |
| Staphylococcus aureus S1199A | 8 | 16 | 0.5 | 1 | 1 | 0.125 |
| Staphylococcus aureus S1199B | 8 | 32 | 2 | 16 | 2 | 1 |
| Staphylococcus haemolyticus 109 | 2 | 16 | 8 | 1 | 4 | 1 |
| Staphylococcus haemolyticus 419 | >64 | 64 | 8 | 8 | 4 | 32 |
| Staphylococcus epidermidis 270 | 32 | 32 | 4 | 4 | 2 | 1 |
| Enterococcus faecium 180 | 2 | 2 | 0.125 | 1 | 1 | 0.5 |
| Enterococcus faecium 180-1 | 1 | 4 | 1 | 0.5 | 1 | <.06 |
| Enterococcus faecalis 2041 | 0.25 | 4 | 0.25 | 2 | 1 | <.06 |
| Enterococcus faecalis 276 | 0.5 | 8 | 0.25 | 2 | 1 | 0.5 |
| Enterococcus gallinarum 245 | 1 | 1 | 0.06 | 1 | 1 | 0.06 |
| Haemophilus influenzae RD | >64 | | >64 | | 2 | >64 |
| Escherichia coli EC14 | >64 | >64 | >64 | >64 | >64 | >64 |
| Streptococcus pyogenes C203 | 0.06 | 1 | 0.06 | 1 | 8 | 0.06 |
| Streptococcus pneumoniae PI | 0.06 | 2 | 0.06 | 2 | 4 | 0.06 |

-41-

TABLE 3
In Vitro Antimicrobial Activity
MIC (mcg/ml)/Compound

| Organism | 47 | 48 | 49 | 50 | 51 | 52 |
|--|-----|-------|------|-------|-----|-----|
| <i>Staphylococcus aureus</i> 446 | 16 | 8 | 0.5 | 2 | 4 | 8 |
| <i>Staphylococcus aureus</i> 489 | 8 | 0.5 | 0.25 | 0.5 | 2 | 4 |
| <i>Staphylococcus aureus</i> 447 | >64 | 32 | 1 | 2 | 4 | 16 |
| <i>Staphylococcus aureus</i> X400 | 16 | 1 | 0.5 | 1 | 4 | 8 |
| <i>Staphylococcus aureus</i> X778 | 8 | 1 | 0.5 | 1 | 2 | 4 |
| <i>Staphylococcus aureus</i> 491 | 8 | 0.5 | <.06 | 0.5 | 2 | 2 |
| <i>Staphylococcus aureus</i> S13E | 32 | 4 | 1 | 1 | 2 | 16 |
| <i>Staphylococcus aureus</i> SAl199 | 16 | 4 | 1 | 1 | 4 | 8 |
| <i>Staphylococcus aureus</i> SAl199A | 4 | 0.5 | 0.5 | 0.25 | 2 | 1 |
| <i>Staphylococcus aureus</i> SAl199B | 16 | 2 | 1 | 1 | 2 | 16 |
| <i>Staphylococcus haemolyticus</i> 105 | 8 | 4 | 1 | 0.5 | 2 | 1 |
| <i>Staphylococcus haemolyticus</i> 415 | 8 | 32 | 2 | 1 | 2 | 8 |
| <i>Staphylococcus epidermidis</i> 270 | 8 | 4 | 0.5 | 1 | 1 | 4 |
| <i>Enterococcus faecium</i> 180 | 2 | 1 | 0.25 | 1 | 2 | 1 |
| <i>Enterococcus faecium</i> 180-1 | 0.5 | 0.25 | <.06 | 0.25 | 0.5 | 0.5 |
| <i>Enterococcus faecalis</i> 2041 | 2 | 0.25 | <.06 | 0.5 | 0.5 | 2 |
| <i>Enterococcus faecalis</i> 276 | 2 | 0.125 | 0.25 | 0.5 | 1 | 2 |
| <i>Enterococcus gallinarum</i> 245 | 2 | 0.06 | 0.06 | 0.5 | 0.5 | 1 |
| <i>Haemophilus influenzae</i> RD | >64 | >64 | | | | |
| <i>Escherichia coli</i> EC14 | >64 | >64 | >64 | >64 | >64 | >64 |
| <i>Streptococcus pyogenes</i> C203 | 2 | 0.06 | 0.06 | 0.125 | 0.5 | 1 |
| <i>Streptococcus pneumoniae</i> PI | 1 | 0.06 | 0.06 | 0.06 | 0.5 | 2 |

-42-
TABLE 4

| In Vitro Activity Against Ent. roosei | | |
|---------------------------------------|------------------------------|------------------------------|
| Cpd. Number | Vancomycin Resistant Strains | Vancomycin Sensitive Strains |
| Vancomycin | 282 | 3.9 |
| A82846B | 29 | 0.22 |
| 1 | 42 | 1.3 |
| 2 | 27 | 1.0 |
| 3 | 27 | 1.5 |
| 4 | 19 | 2.0 |
| 5 | 11 | 0.87 |
| 6 | 32 | 1.3 |
| 7 | 8.0 | 1.3 |
| 8 | 9.5 | 0.87 |
| 9 | 9.5 | 1.2 |
| 10 | >90 | 3.0 |
| 11 | 38 | 1.7 |
| 12 | 4.0 | 0.66 |
| 13 | 9.5 | 1.2 |
| 14 | >64 | 1.0 |
| 15 | 23 | 0.87 |
| 16 | 38 | 1.5 |
| 17 | 4.8 | 0.57 |
| 18 | 19 | 1.0 |
| 19 | 19 | 0.76 |
| 20 | 13 | 1.0 |
| 21 | 2.8 | 0.87 |
| 22 | 6.7 | 0.76 |
| 23 | 1.7 | 0.5 |
| 24 | 4.8 | 1.2 |
| 25 | 6.7 | 1.2 |
| 26 | 4.0 | 1.5 |
| 27 | 3.4 | 1.7 |
| 28 | 9.5 | 6.1 |
| 29 | 38 | 1.3 |
| 30 | 1.7 | 0.38 |
| 31 | 27 | 0.66 |
| 32 | 2.8 | 1.5 |
| 33 | 2.0 | 1.5 |
| 34 | 1.7 | 0.44 |
| 35 | 3.4 | 2.3 |
| 36 | 5.7 | 0.66 |
| 37 | 4.8 | 2.3 |
| 38 | 4.8 | 2.3 |
| 39 | 8 | 5.3 |
| 40 | 11.3 | 0.76 |
| 41 | 64 | 1 |
| 42 | 2.4 | 1.2 |
| 43 | 2.4 | 1.3 |
| 44 | 2 | 1.2 |
| 45 | 3.4 | 1.5 |
| 46 | 4.8 | 0.57 |
| 47 | 6.7 | 4 |

| In Vitro Activity Against Enterococci | | |
|---------------------------------------|----------------------|---------------------|
| Cpd. Number | Vancomycin Resistant | Vancomycin Sensitiv |
| | Strains | Strains |
| 48 | 22 | 0.57 |
| 49 | 2 | 0.38 |
| 50 | 3.4 | 0.38 |
| 51 | 2.4 | 0.38 |
| 52 | 128 | 4.6 |

- 44 -

WE CLAIM

1. A method of treating a bacterial infection in a host comprising the step of administering to the host an effective
5 amount of glycopeptide dimer in which two glycopeptide units are covalently linked to one another through an amine function of an amino sugar.
2. The method of Claim 1 in which both glycopeptide units are A82846B.
- 10 3. The method of Claim 1 in which both glycopeptide units are vancomycin.
4. A method of Claim 1 wherein the bacterial infection is attributable to a vancomycin-resistant-enterococcus.
5. A glycopeptide dimer in which two glycopeptide units are
15 covalently linked to one another through an amine function of an amino sugar, for use in antibacterial therapy.
6. A glycopeptide dimer in which two glycopeptide units are covalently linked to one another through an amine function of an amino sugar, for use in antibacterial therapy against
20 vancomycin-resistant-enterococcus.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/05659

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/00, 38/12, 38/14; C07K 9/00

US CL : 514/2, 8, 9; 530/317, 322, 323

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 8, 9; 530/317, 322, 323

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE (WORD AND STRUCTURE SEARCH), EMBASE, BIOSIS, MEDLINE, WPIDS. SEARCH TERMS: GLYCOPEPTIDE?, VANCOMYCIN?, A828467, DIMER?, SCHIFF BASE?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---------------|---|-----------------------|
| X --- Y | GERHARD et al., The Role of Sugar And Chlorine Substituents in The Dimerization of Vancomycin Antibiotics. J. Am. Chem. Soc., January 1993, Vol. 115, No. 1, pages 232-237, see entire article. | 5-6 ---- 1-6 |
| X --- Y | GROVES et al, The structure of an asymmetric dimer relevant to the mode of action of the glycopeptide antibiotics. Structure, August 1994, Vol. 2, pages 747-754, see entire article. | 5-6 ----- 1-6 |
| A | BEAUREGARD et al, Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrobial Agents and Chemotherapy, March 1995, Vol. 39, No. 3, pages 781-785. | 1-6 |

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

| | | |
|--|-----|--|
| * Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier document published on or after the international filing date | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | | |
| "P" document published prior to the international filing date but later than the priority date claimed | | |

| | |
|---|--|
| Date of the actual completion of the international search 04 JUNE 1997 | Date of mailing of the international search report 20 AUG 1997 |
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 | Authorized officer BENNETT, CELSA Telephone No. (703) 308-0196 |